The global anti-malarial drugs market was valued at US$ 839.1 million in 2019 and is expected to exhibit a CAGR of 4.4% during the forecast period (2019–2027).
Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership, which was established in 1999, with an aim to reduce the burden of malaria in disease-endemic countries by developing novel treatment options. Many of the key pharmaceutical companies have been collaborating with MMV in order to develop novel drug entity for the treatment of malaria. For instance, in December 2019, Ipca Laboratories entered into a collaboration agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation, Atoguanil, a combination of atovaquone and proguanil.
Moreover, rising funding by regional governments is significantly contributing to growth of the global anti-malaria drugs market. These funding are expected to give opportunity for research institutes such as Medicines for Malaria Venture, in order to continue the research studies for potential lead candidates targeting malaria. For instance, in November 2017, United States Agency for International Development (USAID) granted funding of US$ 9 million to Medicines for Malaria Venture for 5 years to conduct the three project including pharmacovigilance study of Pyramax (pyronaridine-artesunate), SERC Phase III study to develop a single-exposure radical cure, and to study the efficacy of DSM265, a potential single-exposure radical cure.
The drug obtained from marine organisms which are being conventionally used like shark and cod-liver oils, sodium alginate, agar-agar, chitin etc.Marine organisms are potential source for drug discovery.
Life has originated from the oceans that cover over 70% of the surface of earth and contain highly ecological, chemical and biological diversity starting from micro-organisms to vertebrates.
This diversity has been the source of unique chemical compounds, which hold tremendous pharmaceutical potential.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-marine-pharmaceuticals-2019-2024-398North America is the largest consumption market of Marine Pharmaceuticals, with sales market share nearly 33.4% in 2018.
The second place is Europe; following North America with the sales market share over 23.3%, China and Japan are also an important sales area.
In 2018, The global marine pharmaceuticals market will observe steady growth because of the robust growth in APAC during the forecast period.
But, the market shares of the Americas and EMEA will decline to some extent during the forecast period.
